82 related articles for article (PubMed ID: 12777741)
1. Assembling a tumor progression model.
Redston M
Methods Mol Biol; 2003; 223():383-401. PubMed ID: 12777741
[No Abstract] [Full Text] [Related]
2. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway.
Tanikawa C; Furukawa Y; Yoshida N; Arakawa H; Nakamura Y; Matsuda K
Oncogene; 2009 Aug; 28(34):3081-92. PubMed ID: 19543321
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Peschos D; Goussia A; Mittari E; Charalabopoulos K; Michael M; Salmas M; Vougiouklakis T; Assimakopoulos D; Agnantis NJ
J Exp Clin Cancer Res; 2004 Jun; 23(2):277-83. PubMed ID: 15354413
[TBL] [Abstract][Full Text] [Related]
4. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
5. Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis.
Pham TT; Ongkeko WM; An Y; Yi ES
Laryngoscope; 2007 Feb; 117(2):253-7. PubMed ID: 17277618
[TBL] [Abstract][Full Text] [Related]
6. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
[TBL] [Abstract][Full Text] [Related]
7. Role of p53 and mismatch repair in PhIP-induced perturbations of the cell cycle.
Duc R; Leong-Morgenthaler PM
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Mar; 802(1):183-7. PubMed ID: 15036010
[TBL] [Abstract][Full Text] [Related]
8. [Differentiation antigens of hemoblastoses and epithelial tumors: relations to the mechanisms of transformation and progression].
Abelev GI
Ontogenez; 2006; 37(3):227-33. PubMed ID: 16813223
[TBL] [Abstract][Full Text] [Related]
9. The disconnection between tumor response and survival.
Mittra I
Nat Clin Pract Oncol; 2007 Apr; 4(4):203. PubMed ID: 17392710
[No Abstract] [Full Text] [Related]
10. Genetic mosaicism in basal cell carcinoma.
Asplund A; Sivertsson A; Bäckvall H; Ahmadian A; Lundeberg J; Ponten F
Exp Dermatol; 2005 Aug; 14(8):593-600. PubMed ID: 16026581
[TBL] [Abstract][Full Text] [Related]
11. In situ assessment of intraepithelial neoplasia in hamster trachea epithelium using angle-resolved low-coherence interferometry.
Chalut KJ; Kresty LA; Pyhtila JW; Nines R; Baird M; Steele VE; Wax A
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):223-7. PubMed ID: 17301253
[TBL] [Abstract][Full Text] [Related]
12. The associated contributions of p53 and the DNA mismatch repair protein Msh6 to spontaneous tumorigenesis.
Young LC; Keuling AM; Lai R; Nation PN; Tron VA; Andrew SE
Carcinogenesis; 2007 Oct; 28(10):2131-8. PubMed ID: 17615258
[TBL] [Abstract][Full Text] [Related]
13. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
[TBL] [Abstract][Full Text] [Related]
14. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
15. The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells.
Chen D; Yu Z; Zhu Z; Lopez CD
Cancer Res; 2006 Apr; 66(7):3485-94. PubMed ID: 16585172
[TBL] [Abstract][Full Text] [Related]
16. p53 in recombination and repair.
Gatz SA; Wiesmüller L
Cell Death Differ; 2006 Jun; 13(6):1003-16. PubMed ID: 16543940
[TBL] [Abstract][Full Text] [Related]
17. The p53 story: layers of complexity.
Braithwaite AW; Royds JA; Jackson P
Carcinogenesis; 2005 Jul; 26(7):1161-9. PubMed ID: 15817608
[TBL] [Abstract][Full Text] [Related]
18. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
[TBL] [Abstract][Full Text] [Related]
20. [Abnormal expression of fragile histidine triad (FHIT) and Mut S homolog 2 (MSH2) proteins in human sporadic colorectal carcinoma and their clinical significance].
Yao CC; Lin CY; Hu MB
Ai Zheng; 2004 Mar; 23(3):310-6. PubMed ID: 15025965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
